CHA Biotech Co. Ltd Total Assets
CHA Biotech Co. Ltd total assets. Based on the latest financial reports, CHA Biotech Co. Ltd (085660) holds total assets worth ₩2.86 Trillion KRW (≈ $1.94 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CHA Biotech Co. Ltd (085660) total market value for the company's overall valuation and market capitalisation.
Total Assets of CHA Biotech Co. Ltd (2008–2025)
Total assets of CHA Biotech Co. Ltd from 2008 to 2025. This chart illustrates how CHA Biotech Co. Ltd's total assets have evolved over time, based on quarterly financial data. See CHA Biotech Co. Ltd share price for real-time trading data and today's change.
CHA Biotech Co. Ltd - Asset Composition Analysis
CHA Biotech Co. Ltd Total Assets Breakdown (December 2025)
CHA Biotech Co. Ltd total assets breakdown as of December 2025. CHA Biotech Co. Ltd's total assets of ₩2.86 Trillion consist of 34.9% current assets and 65.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 9.3% |
| Accounts Receivable | ₩134.96 Billion | 5.3% |
| Inventory | ₩59.60 Billion | 2.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩30.65 Billion | 1.2% |
| Goodwill | ₩196.14 Billion | 7.7% |
Asset Composition Trend (2008–2025)
This chart illustrates how CHA Biotech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of CHA Biotech Co. Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CHA Biotech Co. Ltd's current assets represent 34.9% of total assets in 2025, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2025, up from 3.7% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 7.7% of total assets.
CHA Biotech Co. Ltd Competitors by Total Assets
Key competitors of CHA Biotech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
CHA Biotech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.89 | 0.72 | 1.56 |
| Quick Ratio | 0.84 | 0.68 | 1.49 |
| Cash Ratio | 0.00 | 0.00 | 0.32 |
| Working Capital | ₩-123.27 Billion | ₩-306.14 Billion | ₩197.18 Billion |
CHA Biotech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between CHA Biotech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.82 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 16.1% |
| Total Assets | ₩2.55 Trillion |
| Market Capitalization | $428.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values CHA Biotech Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CHA Biotech Co. Ltd's assets grew by 16.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CHA Biotech Co. Ltd (2008–2025)
The table below shows the annual total assets of CHA Biotech Co. Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩2.55 Trillion ≈ $1.73 Billion |
+16.10% |
| 2024-12-31 | ₩2.19 Trillion ≈ $1.49 Billion |
+27.17% |
| 2023-12-31 | ₩1.73 Trillion ≈ $1.17 Billion |
+7.38% |
| 2022-12-31 | ₩1.61 Trillion ≈ $1.09 Billion |
+4.68% |
| 2021-12-31 | ₩1.54 Trillion ≈ $1.04 Billion |
+16.85% |
| 2020-12-31 | ₩1.31 Trillion ≈ $890.28 Million |
+12.97% |
| 2019-12-31 | ₩1.16 Trillion ≈ $788.10 Million |
+22.73% |
| 2018-12-31 | ₩947.53 Billion ≈ $642.13 Million |
+19.40% |
| 2017-12-31 | ₩793.61 Billion ≈ $537.82 Million |
+3.21% |
| 2016-12-31 | ₩768.93 Billion ≈ $521.09 Million |
+19.25% |
| 2015-12-31 | ₩644.83 Billion ≈ $436.99 Million |
+3.86% |
| 2014-12-31 | ₩620.88 Billion ≈ $420.76 Million |
-9.42% |
| 2013-12-31 | ₩685.47 Billion ≈ $464.53 Million |
+32.21% |
| 2012-12-31 | ₩518.47 Billion ≈ $351.36 Million |
+9.15% |
| 2011-12-31 | ₩475.02 Billion ≈ $321.91 Million |
+42.09% |
| 2010-12-31 | ₩334.30 Billion ≈ $226.55 Million |
+46.40% |
| 2009-12-31 | ₩228.35 Billion ≈ $154.75 Million |
+119.83% |
| 2008-12-31 | ₩103.88 Billion ≈ $70.40 Million |
-- |
About CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more